These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20195905)

  • 21. Healing erosive esophagitis with a proton pump inhibitor: the more the merrier?
    Fass R
    Am J Gastroenterol; 2012 Apr; 107(4):531-3. PubMed ID: 22475962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dexlansoprazole MR: a review.
    Hershcovici T; Jha LK; Fass R
    Ann Med; 2011 Aug; 43(5):366-74. PubMed ID: 21366513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dexlansoprazole (Kapidex) for GERD and erosive esophagitis.
    Med Lett Drugs Ther; 2009 Mar; 51(1308):21-2. PubMed ID: 19305367
    [No Abstract]   [Full Text] [Related]  

  • 24. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
    Fass R; Johnson DA; Orr WC; Han C; Mody R; Stern KN; Pilmer BL; Perez MC
    Am J Gastroenterol; 2011 Mar; 106(3):421-31. PubMed ID: 21224838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease.
    Fiedorek S; Tolia V; Gold BD; Huang B; Stolle J; Lee C; Gremse D
    J Pediatr Gastroenterol Nutr; 2005 Mar; 40(3):319-27. PubMed ID: 15735486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
    Tolia V; Gilger MA; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26422096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
    Emerson CR; Marzella N
    Clin Ther; 2010 Aug; 32(9):1578-96. PubMed ID: 20974316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of rabeprazole treatment on health-related quality of life and symptoms in patients with reflux esophagitis: a prospective multicenter observational study in Japan.
    Hongo M; Miwa H; Kusano M;
    J Gastroenterol; 2011 Mar; 46(3):297-304. PubMed ID: 21082202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D; Paré P; Pericak D; Pyzyk M;
    Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
    Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
    Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
    Robinson M; Fitzgerald S; Hegedus R; Murthy A; Jokubaitis L;
    Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis.
    Baker R; Tsou VM; Tung J; Baker SS; Li H; Wang W; Rath N; Maguire MK; Comer GM
    Clin Pediatr (Phila); 2010 Sep; 49(9):852-65. PubMed ID: 20522615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis.
    Raghunath AS; Green JR; Edwards SJ
    Clin Ther; 2003 Jul; 25(7):2088-101. PubMed ID: 12946553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis.
    Kindt S; Imschoot J; Tack J
    Dis Esophagus; 2011 Nov; 24(8):531-7. PubMed ID: 21418126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis.
    Fock KM; Ang TL
    Curr Opin Investig Drugs; 2008 Oct; 9(10):1108-15. PubMed ID: 18821474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.
    Fennerty MB; Johanson JF; Hwang C; Sostek M
    Aliment Pharmacol Ther; 2005 Feb; 21(4):455-63. PubMed ID: 15709997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis.
    Kovacs TO; Freston JW; Haber MM; Hunt B; Atkinson S; Peura DA
    Dig Dis Sci; 2009 Aug; 54(8):1693-701. PubMed ID: 19267194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of symptoms in step-down therapy of gastroesophageal reflux disease.
    Mine S; Iida T; Tabata T; Kishikawa H; Tanaka Y
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1365-70. PubMed ID: 16105122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life and severity of symptoms among patients with various degrees of reflux esophagitis: a prospective study.
    Mari A; Na'amnih W; Ghantous L; Ahmad HS; Khoury T; Muhsen K
    Sci Rep; 2023 Aug; 13(1):13970. PubMed ID: 37634042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
    Kukulka M; Wu J; Perez MC
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):41-7. PubMed ID: 21716130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.